drugset / Trial / NCT03483883
Avelumab/Gemcitabine in Sarcomatoid RCC
NaSingle-groupOpen-labelTreatment
Summary
To determine the feasibility and safety of avelumab and gemcitabine combination therapy in patients with metastatic sRCC.
Timeline
- Start
- 2018-03-19
- Primary completion
- 2020-07-22
- Completion
- 2021-02-10
Outcome
Outcome not reported
Stopped (Enrollment): “The study was terminated due to protracted accrual and limited patient engagement in the setting of rapidly changing treatment paradigms for advanced RCC with sarcomatoid features and/or intermediate/poor risk clinical features.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Gemcitabine | Small molecule | 1250 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1500 mg/m2 | Intravenous |